DELFI Diagnostics, Inc. and Incendia Therapeutics are collaborating to employ DELFI's advanced treatment monitoring test in Incendia's Phase 1 clinical trial (NCT05753722). The collaboration aims to enhance patient outcomes through precision medicine by leveraging DELFI Diagnostics' DELFI-TF Monitoring assay.
Incendia Therapeutics is focused on discovering and developing a novel class of experimental therapeutics designed to reprogram the tumor microenvironment (TME).
DELFI-TF Assay for Treatment Monitoring
The DELFI-TF assay offers a unique and cost-effective approach to monitoring cfDNA in patients participating in clinical research studies. According to Nicholas Dracopoli, Co-Founder and Chief Scientific Officer at DELFI Diagnostics, the assay provides evidence of the efficacy of a New Molecular Entity (NME) in the early phases of clinical development, offering valuable insights for managing Phase 1 programs.
A key advantage of the DELFI-TF assay is its minimal plasma requirement, needing less than 1 mL of plasma, which is considerably less than other cfDNA assays. This is particularly beneficial in early clinical studies that require large blood volumes for other assessments, such as pharmacokinetic (PK) analyses.
Incendia's Commitment to Precision Medicine
Susan Macdonald, PhD, SVP Nonclinical Development & Strategy at Incendia Therapeutics, emphasized Incendia's commitment to developing novel, precision medicines for patients in need. She noted that innovative products like those developed by DELFI will aid in the efficient progress of these medicines through the clinic, leveraging the strengths of both companies to bring a state-of-the-art detection tool to scientific researchers.
